{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-264916","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-06-10T11:32:05+00:00","discovered_at":"2026-06-10T11:35:00.291931+00:00","generated_at":"2026-06-10T11:35:42.463225+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cullinan Therapeutics reports positive clinical data for CLN-978 and velinotamig in autoimmune diseases","bullets":["CLN-978 achieved DAS28-ESR remission in a rituximab-refractory RA patient, reducing score from 4.0 to 2.2 at week 4.","First three SLE patients on CLN-978 multi-dose showed safety consistent with EULAR 2026 data; rapid proteinuria improvement supports lupus nephritis trial.","Velinotamig (BCMA TCE) induced complete renal responses in two SLE patients; SLEDAI-2K scores dropped to 0 and 2 at week 8.","Cullinan plans Phase 2a expansion for CLN-978 in lupus nephritis in early 2027 and Phase 1/2a for velinotamig in autoimmune cytopenias in Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-264916","json":"https://secwatch.observer/filing/0001193125-26-264916.json","markdown":"https://secwatch.observer/filing/0001193125-26-264916.md","text":"https://secwatch.observer/filing/0001193125-26-264916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/0001193125-26-264916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T11:35:42.463225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}